News
COCP
0.3800
-7.32%
-0.0300
Cocrystal Pharma Expands Collaboration With The National Institute Of Allergy And Infectious Diseases To Evaluate COVID-19 Protease Inhibitors
Cocrystal Pharma, Inc. (NASDAQ:COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for
Benzinga · 06/01 12:01
Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors
BOTHELL, Wash., June 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for explorato...
GlobeNewswire · 06/01 12:00
Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference
BOTHELL, Wash., May 18, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a Company overview at the H.C. Wainwright Global Investment Con...
GlobeNewswire · 05/18 12:00
COCP: Cocrystal Pharma Releases 2022 1st Quarter Results and Provides an Update on the Current Pipeline Programs
By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT
Benzinga · 05/12 16:10
Recap: Cocrystal Pharma Q1 Earnings
  Cocrystal Pharma (NASDAQ:COCP) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/11 12:35
BRIEF-Cocrystal Pharma Reports First Quarter 2022 Financial Results
reuters.com · 05/11 12:06
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
Reported favorable preliminary data from the two initial cohorts in its Phase 1 study with CC-42344 for the treatment of pandemic and seasonal influenza AAnnounced a collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) to ev...
GlobeNewswire · 05/11 12:00
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 04/21 14:15
Cocrystal, NIAID ink pact to explore COVID-19 protease inhibitors in preclinical studies
Cocrystal Pharma (NASDAQ:COCP) signed an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) for preclinical studies evaluating the potential of  its 3CL protease inhibitors to treat COVID-19.
Seekingalpha · 04/21 13:48
Cocrystal Pharma Collaborates With The National Institute Of Allergy And Infectious Diseases To Evaluate COVID-19 Protease Inhibitors
Cocrystal Pharma, Inc. (NASDAQ:COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for
Benzinga · 04/21 12:02
Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors
BOTHELL, Wash., April 21, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for explorat...
GlobeNewswire · 04/21 12:00
Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference
BOTHELL, Wash., April 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, PhD, President and co-interim Chief Executive Officer, will present a Company overview at the hybrid in-person and virtual Life Science Innovat...
GlobeNewswire · 04/19 12:00
Cocrystal Pharma to Present at the Noble Capital Markets’ NobleCon18 Conference
BOTHELL, Wash., April 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a Company overview at the NobleCon18—Noble Capital Markets’ E...
GlobeNewswire · 04/14 12:00
Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial
Cocrystal Pharma Inc (NASDAQ: COCP) 
Benzinga · 04/12 15:01
Cocrystal Pharma oral antiviral CC-42344 for influenza A shows safety in interim phase 1 data
Cocrystal Pharma (NASDAQ:COCP) said preliminary data from a phase 1 study of CC-42344 showed a favorable safety and pharmacokinetic profile of the oral antiviral for pandemic and seasonal influenza A.
Seekingalpha · 04/12 13:32
BRIEF-Cocrystal Pharma Reports Favorable Prelim Data From Phase 1 Initial Cohorts With CC-42344
reuters.com · 04/12 12:14
Cocrystal Pharma Announces Favorable Results in Phase 1 Study of Antiviral Against Influenza A
MT Newswires · 04/12 09:36
10 Biotech Penny Stocks with Growth Catalysts
In this article, we discuss 10 biotech penny stocks with growth catalysts. If you want to see some more stocks in this selection, check out 5 Biotech Penny Stocks with Growth Catalysts. According to Global Market Insights, the market for biotech in 2020 wa...
Insider Monkey · 04/06 14:15
We're Hopeful That Cocrystal Pharma (NASDAQ:COCP) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 03/30 18:57
COCP: Cocrystal Pharma releases 2021 fiscal year results and provides an update on the current pipeline programs
By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT
Benzinga · 03/30 11:42
More
Webull provides a variety of real-time COCP stock news. You can receive the latest news about Cocrystal Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About COCP
Cocrystal Pharma, Inc. is a biotechnology company. The Company focuses on developing antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. The Company focuses on treating influenza virus, coronavirus, hepatitis C virus (HCV) and norovirus infections by discovering and developing drug candidates targeting the viral replication process. The Company uses computational methods to screen and design product candidates using cocrystal structural information. Its development pipeline includes CC-31244 and CC-42344. The Company’s CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a PB2 inhibitor for the treatment of influenza A infection. Its pipeline also includes CDI-45205 for the treatment of coronavirus. It has also developed chemical libraries consisting of non-nucleoside inhibitors, metal-binding inhibitors, and drug-like fragments.